Biological specimens are the centerpiece ot research efforts geared to translate laboratory discoveries into patients. High quality procurement, processing, diagnosis, annotation, storage, and distribution of pathology tissue specimens are vital to translational research. Approximately 1000 radical prostatectomies are performed per year at our institution and we currently have over 14,000 such patients in our database, 6.5% of which are from African Americans. We have collected fresh frozen prostate tumor tissues from more than 1900 patients, represented by more than 7000 frozen tissue blocks. We have created tissue microarrays containing prostate cancer from 926 patients, most with long term follow-up. Core B has the following Specific Aims: 1)To maintain and enhance a repository of prostate tissues containing a wide range of neoplastic and non-neoplastic samples from both fresh frozen and paraffin blocks, prostatic fluids, DMA, RNA, and protein, and, to distribute these samples to SPORE and other investigators;2) to provide high quality histopathologic diagnoses of tissue specimens and tissue microarrays;3) To perform well-controlled immunohistochemistry (IHC) assays, interpretation and quantitative analyses of IHC slides to facilitate individual research projects;4) To continue to design, produce and distribute tissue microarrays using human prostate tissues, cell lines, and xenografts;5) To continue to improve and add tools to our open source tissue microarray database and software (TMAJ) (http://tmaj.pathology.jhmi.edu) including the development of new open source image analysis tools """"""""FRIDA"""""""" (FRamework for Image Dataset Analysis) while ensuring compatibility with the CaBIG grid system. 6) To test emerging software tools, such as CaTissue, from the CaBIG program for specimen banking efforts, serving as a model for other SPOREs and other research programs throughout our University. 7) To provide a facility and pathology expertise for laser capture microdissection;8) To continue to function as the Central Pathology Core for the Inter-Prostate SPORE Biomarker Study (IPBS). The continued enhancement of these resources will facilitate development of biological markers geared to disease prevention, diagnosis, assessment of prognosis, prediction for drug treatment response, and monitoring response to therapy?developments needed to achieve the ultimate goal of eliminating suffering and death from prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058236-17
Application #
8323095
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
17
Fiscal Year
2011
Total Cost
$194,874
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jiang, Wen; Ulmert, David; Simons, Brian W et al. (2018) The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates. Nucl Med Biol 62-63:1-8
Tsang, Sabrina H; Peisch, Samuel F; Rowan, Brendan et al. (2018) Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer :
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Kaur, Harsimar B; Guedes, Liana B; Lu, Jiayun et al. (2018) Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 31:1539-1552
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 750 publications